Minerva Neurosciences (NERV) Competitors $1.45 +0.07 (+5.07%) Closing price 05/21/2025 03:57 PM EasternExtended Trading$1.42 -0.02 (-1.72%) As of 05/21/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NERV vs. MURA, NBRV, QNCX, IPSC, KRON, BDRX, MRSN, PMVP, HOWL, and CNTBShould you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include Mural Oncology (MURA), Nabriva Therapeutics (NBRV), Quince Therapeutics (QNCX), Century Therapeutics (IPSC), Kronos Bio (KRON), Biodexa Pharmaceuticals (BDRX), Mersana Therapeutics (MRSN), PMV Pharmaceuticals (PMVP), Werewolf Therapeutics (HOWL), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical products" industry. Minerva Neurosciences vs. Mural Oncology Nabriva Therapeutics Quince Therapeutics Century Therapeutics Kronos Bio Biodexa Pharmaceuticals Mersana Therapeutics PMV Pharmaceuticals Werewolf Therapeutics Connect Biopharma Minerva Neurosciences (NASDAQ:NERV) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations. Do insiders & institutionals have more ownership in NERV or MURA? 34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 80.2% of Mural Oncology shares are owned by institutional investors. 8.6% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 0.1% of Mural Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts prefer NERV or MURA? Minerva Neurosciences currently has a consensus price target of $5.00, indicating a potential upside of 244.83%. Mural Oncology has a consensus price target of $13.00, indicating a potential upside of 371.01%. Given Mural Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Mural Oncology is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the MarketBeat Community prefer NERV or MURA? Minerva Neurosciences received 339 more outperform votes than Mural Oncology when rated by MarketBeat users. However, 80.00% of users gave Mural Oncology an outperform vote while only 55.52% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformMinerva NeurosciencesOutperform Votes34755.52% Underperform Votes27844.48% Mural OncologyOutperform Votes880.00% Underperform Votes220.00% Does the media prefer NERV or MURA? In the previous week, Mural Oncology had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for Mural Oncology and 1 mentions for Minerva Neurosciences. Mural Oncology's average media sentiment score of 1.00 beat Minerva Neurosciences' score of 0.00 indicating that Mural Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mural Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NERV or MURA more profitable? Minerva Neurosciences' return on equity of 0.00% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -6.74% Mural Oncology N/A -70.10%-61.30% Which has more volatility & risk, NERV or MURA? Minerva Neurosciences has a beta of -0.5, suggesting that its stock price is 150% less volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 3.91, suggesting that its stock price is 291% more volatile than the S&P 500. Which has stronger earnings & valuation, NERV or MURA? Mural Oncology is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$30M$0.821.77Mural OncologyN/AN/A-$207.45M-$7.67-0.36 SummaryMural Oncology beats Minerva Neurosciences on 9 of the 15 factors compared between the two stocks. Get Minerva Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NERV vs. The Competition Export to ExcelMetricMinerva NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.65M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-3.308.9226.7719.71Price / SalesN/A253.80393.17117.39Price / CashN/A65.8538.2534.62Price / Book-0.366.466.794.50Net Income-$30M$143.98M$3.23B$248.18M7 Day Performance-6.75%2.03%1.53%0.20%1 Month Performance-15.20%4.11%10.06%12.37%1 Year Performance-42.00%-2.87%16.74%7.04% Minerva Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NERVMinerva Neurosciences2.9277 of 5 stars$1.45+5.1%$5.00+244.8%-41.1%$9.65MN/A-3.309News CoverageAnalyst ForecastMURAMural Oncology2.3182 of 5 stars$2.64+0.4%$13.00+392.4%-26.8%$45.59MN/A-0.29119NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070News CoverageAnalyst ForecastQNCXQuince Therapeutics2.895 of 5 stars$1.03+1.0%$8.00+676.7%+19.8%$45.45MN/A-0.8360IPSCCentury Therapeutics2.489 of 5 stars$0.52-2.3%$4.40+738.6%-80.5%$45.21M$6.59M-0.28170Earnings ReportAnalyst RevisionKRONKronos Bio2.5042 of 5 stars$0.74+2.6%$1.63+119.6%-34.2%$45.12M$9.85M-0.52100High Trading VolumeBDRXBiodexa Pharmaceuticals0.8809 of 5 stars$1.23-12.8%N/AN/A$44.95M$83,000.000.0020High Trading VolumeMRSNMersana Therapeutics3.7886 of 5 stars$0.36+13.1%$3.67+916.8%-86.5%$44.94M$40.50M-0.59150Earnings ReportAnalyst RevisionGap DownPMVPPMV Pharmaceuticals1.6808 of 5 stars$0.86-2.1%$5.67+555.9%-57.7%$44.89MN/A-0.8650Positive NewsHOWLWerewolf Therapeutics3.4911 of 5 stars$1.00+25.0%$8.33+733.3%-78.4%$44.87M$1.89M-0.6540Positive NewsCNTBConnect Biopharma3.2682 of 5 stars$0.80-0.9%$8.00+897.0%-54.0%$44.41M$26.03M0.00110Positive NewsEarnings ReportGap Up Related Companies and Tools Related Companies Mural Oncology Alternatives Nabriva Therapeutics Alternatives Quince Therapeutics Alternatives Century Therapeutics Alternatives Kronos Bio Alternatives Biodexa Pharmaceuticals Alternatives Mersana Therapeutics Alternatives PMV Pharmaceuticals Alternatives Werewolf Therapeutics Alternatives Connect Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NERV) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
